MetaCap

Actuate Therapeutics (ACTU) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Pharmaceuticals (CTXR) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 55.4% versus a loss of 96.4%. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $13.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-96.43%CTXR-55.39%
+32%-35%-103%
Nov 21, 20251 yearNov 20, 2026
ACTU-97.41%CTXR-96.63%
+43%-30%-104%
Aug 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus CTXR key metrics
MetricACTUCTXR
Share price$0.2253$0.5085
Market cap$13.60M$13.96M
1-day change+5.38%+2.27%
YTD return-96.32%-34.56%
1-year return-96.43%-55.39%
5-year return—-98.79%
EPS (TTM)$-0.76$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.23M$-39.74M
52-week high$7.90$1.54
52-week low$0.174$0.37
Distance from 52-week high-97.15%-66.98%
Analyst consensusnonenone
Avg. price target upside+5084.20%+686.63%
Average volume807.24K275.44K
Shares outstanding60.38M27.45M
Employees1223
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTXR has outperformed ACTU by 41.0 percentage points over the past year.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

ACTU vs CTXR FAQ

Which is bigger, Actuate Therapeutics or Citius Pharmaceuticals?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $13.60M for Actuate Therapeutics (ACTU).

Which stock has performed better over the past year, ACTU or CTXR?

CTXR returned -55.39% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.

Are Actuate Therapeutics and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons